ARID1A-mutant and deficient bladder cancer is sensitive to EZH2 pharmacologic inhibition
J. E. Ferguson, H. Rehman, D. S. Chandrashekar, B. Chakravarthi, S. Nepal, M.-L. Eich, A. Robinson, S. Agarwal, S. A. H. Balasubramanya, G. Naik, U. Manne, G. Netto, C.-x. Pan, G. Sonpavde, S. Varambally
This study shows that ARID1A-deficient bladder cancer cells are sensitive to EZH2 inhibition, suggesting a therapeutic strategy for patients with ARID1A mutations.
bioRxiv · Jan 12, 2021 · PreprintCancer Biology